Holen Sie sich die Stockscreener-App
53.01
2.16%
1.12
Vorhandelsmarkt:
53.75
0.74
+1.40%
Schlusskurs vom Vortag:
$51.89
Offen:
$52.22
24-Stunden-Volumen:
2.29M
Relative Volume:
1.47
Marktkapitalisierung:
$7.18B
Einnahmen:
$2.51B
Nettoeinkommen (Verlust:
$185.56M
KGV:
39.56
EPS:
1.34
Netto-Cashflow:
$517.59M
1W Leistung:
-5.12%
1M Leistung:
-8.40%
6M Leistung:
-43.20%
1J Leistung:
-27.81%
1-Tages-Spanne:
$52.01
$53.60
1-Wochen-Bereich:
$51.87
$57.99
52-Wochen-Spanne:
$51.87
$94.93
Globus Medical Inc Stock (GMED) Company Profile
Firmenname
Globus Medical Inc
Sektor
Branche
Telefon
610-930-1800
Adresse
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Vergleichen Sie GMED mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
53.01 | 7.56B | 2.51B | 185.56M | 517.59M | 1.34 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-01-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-19 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-02-10 | Herabstufung | Loop Capital | Buy → Hold |
| 2023-02-10 | Herabstufung | Needham | Buy → Hold |
| 2023-02-10 | Herabstufung | Truist | Buy → Hold |
| 2023-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-29 | Eingeleitet | Loop Capital | Buy |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2020-12-08 | Eingeleitet | Citigroup | Buy |
| 2020-10-20 | Eingeleitet | Stifel | Hold |
| 2020-08-06 | Bestätigt | Needham | Buy |
| 2020-08-06 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Eingeleitet | Northland Capital | Market Perform |
| 2020-07-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Bestätigt | Needham | Buy |
| 2020-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Bestätigt | Needham | Buy |
| 2019-05-24 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Bestätigt | Needham | Buy |
| 2019-02-28 | Hochstufung | UBS | Neutral → Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Bestätigt | Needham | Buy |
| 2018-04-04 | Hochstufung | Needham | Hold → Buy |
Alle ansehen
Globus Medical Inc Aktie (GMED) Neueste Nachrichten
Globus Medical Names Keith Pfeil as CEO, Posts Strong Q2 Sales Growth - MyChesCo
What analysts say about Globus Medical Inc. stockFree Predictions - jammulinksnews.com
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply - MedTech Dive
Globus Medical Inc. Stock Analysis and ForecastFree Stock Market Mentorship - jammulinksnews.com
Is Globus Medical Inc. a good long term investmentBreakthrough wealth creation - jammulinksnews.com
Globus Medical to Announce Q2 2025 Financial Results on August 7, Followed by Investor Call - MSN
Spinal Non-Fusion Technologies Market Set to Witness - openPR.com
Globus Medical CEO leaves for Dentsply Sirona corner office - MassDevice
Globus Medical Appoints Keith Pfeil as CEO - citybiz
Avantor and Globus Medical appoint new CEOs - The Business Journals
What You Can Learn From Globus Medical, Inc.'s (NYSE:GMED) P/E - simplywall.st
Why Globus Medical (GMED) Shares Are Trading Lower Today - Yahoo Finance
Globus Medical stock holds steady as Needham maintains rating amid CEO change - Investing.com Canada
Globus CEO leaving, analysts see replacement as steady hand - BioWorld MedTech
Globus Medical's Leadership Transition: A Strategic Catalyst for Long-Term Growth in the Medical Technology Sector - AInvest
Globus Medical's Leadership Transition and Growth Potential in a Post-Merger Landscape - AInvest
Globus Medical stock hits 52-week low at 53.54 USD By Investing.com - Investing.com Canada
Dentsply Sirona Hires Globus CEO Daniel Scavilla as Chief Exec - Medical Product Outsourcing
Impingement Syndrome Market Growing with Musculoskeletal - openPR.com
Globus Medical Announces New CEO and CFO - TipRanks
Globus Medical appoints Keith Pfeil as new CEO, reports Q2 sales growth By Investing.com - Investing.com South Africa
Dentsply Sirona Appoints Daniel Scavilla as President and CEO, Effective August 1, 2025 - Quiver Quantitative
Globus Medical sees Q2 revenue $745.3M, consensus $738.91M - TipRanks
Former Globus Medical CEO Takes Helm at Dentsply Sirona as Q2 Sales Hit $935M - Stock Titan
Globus Medical's Leadership Transition and Q2 Sales Performance: A Strategic Blueprint for Sustained Growth in Musculoskeletal Tech - AInvest
Globus Medical appoints Keith Pfeil as new CEO, reports Q2 sales growth - Investing.com
Globus Medical Expands Surgical Navigation Portfolio With Advanced DuraPro Oscillating System - MSN
GMED names new CEO & CFO after sudden resignation – compensation, details - Stock Titan
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results - GlobeNewswire
Globus Medical Shakes Up Leadership: New CEO Takes Helm as Q2 Sales Hit Record $745M, Up 18% - Stock Titan
What drives Globus Medical Inc. stock priceUnbelievable profit margins - printweek.in
GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain? - MSN
Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth - MedTech Dive
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED) - The Globe and Mail
Globus Medical Schedules Second Quarter Earnings Release and Conference Call | GMED Stock News - GuruFocus
Globus Medical, Inc. to Announce Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Globus Medical Schedules Second Quarter Earnings Release and Conference Call - GlobeNewswire
Globus Medical Q2 Earnings Coming August 7: Key Focus on Musculoskeletal Tech Growth - Stock Titan
Globus Medical (GMED) Fell 19% in Q2 - MSN
Piper Sandler Maintained a Buy Rating on Globus Medical (GMED), Kept the PT Unchanged - Insider Monkey
Globus Medical expands Excelsius navigation capabilities - MassDevice
12 Best 52-Week Low Stocks to Buy According to Analysts - Insider Monkey
Bone Graft Harvester Market Future Business Opportunities - openPR.com
Finanzdaten der Globus Medical Inc-Aktie (GMED)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):